Research advances in the association between activating transcription factor 3 and chronic liver diseases

Qunli GU; Hui LI; Xiuxiu DENG; Zijian ZENG; Haijian DONG

doi:10.3969/j.issn.1001-5256.2021.09.047

Volume 37 Issue 9

Sep. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(9): 2236-2240

PDF( 2007 KB)

Research advances in the association between activating transcription factor 3 and chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2021.09.047

Qunli GU^{1, 2},
Hui LI^{1
,
,},
Xiuxiu DENG^{1, 2},
Zijian ZENG^{1, 2},
Haijian DONG^{1, 2}

1.
Central Laboratory, The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
2.
School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China

Research funding:

Key R & D Projects of Sichuan Provincial Department of Science and Technology (20ZDYF2153)

Received Date: 2021-02-03
Accepted Date: 2021-02-23
Published Date: 2021-09-20

Abstract

Abstract

Activating transcription factor 3 (ATF3) belongs to the transcription factor ATF/CREB family and is a stress-induced adaptive response gene. ATF3 is involved in the regulation of various cell activities to adapt to the changes in intracellular and extracellular environments. Recent studies have shown that ATF3 plays an important role in the development and progression of various chronic liver diseases, including nonalcoholic fatty liver disease, liver fibrosis, and liver cancer, by regulating gluconeogenesis, lipid metabolism, and immune function. This article reviews the mechanism of action of ATF3 in chronic liver diseases.
- Activating Transcription Factor 3,
- Non-alcoholic Fatty Liver Disease,
- Liver Cirrhosis,
- Liver Neoplasms

FullText(HTML)

References(40)

References

[1]	HAI T, WOLFORD CC, CHANG YS. ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: Is modulation of inflammation a unifying component?[J]. Gene Expr, 2010, 15(1): 1-11. DOI: 10.3727/105221610x12819686555015.
[2]	ROHINI M, HARITHA MENON A, et al. Role of activating transcription factor 3 and its interacting proteins under physiological and pathological conditions[J]. Int J Biol Macromol, 2018, 120(Pt A): 310-317. DOI: 10.1016/j.ijbiomac.2018.08.107.
[3]	UDAYAKUMAR TS, STOYANOVA R, SHAREEF MM, et al. Edelfosine promotes apoptosis in androgen-deprived prostate tumors by increasing ATF3 and inhibiting androgen receptor activity[J]. Mol Cancer Ther, 2016, 15(6): 1353-1363. DOI: 10.1158/1535-7163.MCT-15-0332.
[4]	JOO JH, UEDA E, BORTNER CD, et al. Farnesol activates the intrinsic pathway of apoptosis and the ATF4-ATF3-CHOP cascade of ER stress in human T lymphoblastic leukemia Molt4 cells[J]. Biochem Pharmacol, 2015, 97(3): 256-268. DOI: 10.1016/j.bcp.2015.08.086.
[5]	CHUEH AC, TSE J, IOANNIDIS P, et al. Abstract 4728: Histone deacetylase inhibitors induce apoptosis in multiple tumor types through induction of ATF3[J]. Cancer Res, 2016, 76(14): 4728-4728. DOI: 10.1158/1538-7445.
[6]	ZHAO J, LI X, GUO M, et al. The common stress responsive transcription factor ATF3 binds genomic sites enriched with p300 and H3K27ac for transcriptional regulation[J]. BMC Genomics, 2016, 17: 335. DOI: 10.1186/s12864-016-2664-8.
[7]	FUKASAWA K, PARK G, IEZAKI T, et al. ATF3 controls proliferation of osteoclast precursor and bone remodeling[J]. Sci Rep, 2016, 6: 30918. DOI: 10.1038/srep30918.
[8]	JEONG BC, KIM JH, KIM K, et al. ATF3 modulates calcium signaling in osteoclast differentiation and activity by associating with c-Fos and NFATc1 proteins[J]. Bone, 2017, 95: 33-40. DOI: 10.1016/j.bone.2016.11.005.
[9]	WANG Z, YAN C. Emerging roles of ATF3 in the suppression of prostate cancer[J]. Mol Cell Oncol, 2016, 3(1): e1010948. DOI: 10.1080/23723556.2015.1010948.
[10]	GUO N, MENG C, BAI W, et al. Prostaglandin F2α induces expression of activating transcription factor 3 (ATF3) and activates MAPK signaling in the rat corpus luteum[J]. Acta Histochem, 2015, 117(2): 211-218. DOI: 10.1016/j.acthis.2014.12.008.
[11]	JE YJ, CHOI DK, SOHN KC, et al. Inhibitory role of Id1 on TGF-β-induced collagen expression in human dermal fibroblasts[J]. Biochem Biophys Res Commun, 2014, 444(1): 81-85. DOI: 10.1016/j.bbrc.2014.01.010.
[12]	GOKULNATH M, PARTRIDGE NC, SELVAMURUGAN N. Runx2, a target gene for activating transcription factor-3 in human breast cancer cells[J]. Tumour Biol, 2015, 36(3): 1923-1931. DOI: 10.1007/s13277-014-2796-x.
[13]	KU HC, CHENG CF. Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer[J]. Front Endocrinol (Lausanne), 2020, 11: 556. DOI: 10.3389/fendo.2020.00556.
[14]	ALLEN-JENNINGS AE, HARTMAN MG, KOCIBA GJ, et al. The roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver dysfunction and defects in endocrine pancreas[J]. J Biol Chem, 2001, 276(31): 29507-29514. DOI: 10.1074/jbc.M100986200.
[15]	ALLEN-JENNINGS AE, HARTMAN MG, KOCIBA GJ, et al. The roles of ATF3 in liver dysfunction and the regulation of phosphoenolpyruvate carboxykinase gene expression[J]. J Biol Chem, 2002, 277(22): 20020-20025. DOI: 10.1074/jbc.M200727200.
[16]	KIM JY, SONG EH, LEE HJ, et al. Chronic ethanol consumption-induced pancreatic {beta}-cell dysfunction and apoptosis through glucokinase nitration and its down-regulation[J]. J Biol Chem, 2010, 285(48): 37251-37262. DOI: 10.1074/jbc.M110.142315.
[17]	JANG MK, PARK HJ, JUNG MH. ATF3 represses PDX-1 expression in pancreatic β-cells[J]. Biochem Biophys Res Commun, 2011, 412(2): 385-390. DOI: 10.1016/j.bbrc.2011.07.108.
[18]	TSAI WW, MATSUMURA S, LIU W, et al. ATF3 mediates inhibitory effects of ethanol on hepatic gluconeogenesis[J]. Proc Natl Acad Sci U S A, 2015, 112(9): 2699-2704. DOI: 10.1073/pnas.1424641112.
[19]	KIM JY, LEE SH, SONG EH, et al. A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: Controlled by ATF3[J]. Cell Signal, 2009, 21(12): 1758-1767. DOI: 10.1016/j.cellsig.2009.07.011.
[20]	JANG MK, SON Y, JUNG MH. ATF3 plays a role in adipocyte hypoxia-mediated mitochondria dysfunction in obesity[J]. Biochem Biophys Res Commun, 2013, 431(3): 421-427. DOI: 10.1016/j.bbrc.2012.12.154.
[21]	JANG MK, KIM CH, SEONG JK, et al. ATF3 inhibits adipocyte differentiation of 3T3-L1 cells[J]. Biochem Biophys Res Commun, 2012, 421(1): 38-43. DOI: 10.1016/j.bbrc.2012.03.104.
[22]	JANG MK, JUNG MH. ATF3 represses PPARγ expression and inhibits adipocyte differentiation[J]. Biochem Biophys Res Commun, 2014, 454(1): 58-64. DOI: 10.1016/j.bbrc.2014.10.028.
[23]	CHENG CF, KU HC, CHENG JJ, et al. Adipocyte browning and resistance to obesity in mice is induced by expression of ATF3[J]. Commun Biol, 2019, 2: 389. DOI: 10.1038/s42003-019-0624-y.
[24]	KIM S, SONG NJ, BAHN G, et al. ATF3 induction is a therapeutic target for obesity and metabolic diseases[J]. Biochem Biophys Res Commun, 2018, 504(4): 903-908. DOI: 10.1016/j.bbrc.2018.09.048.
[25]	LIU YF, WEI JY, SHI MH, et al. Glucocorticoid induces hepatic steatosis by inhibiting activating transcription factor 3 (ATF3)/S100A9 protein signaling in granulocytic myeloid-derived suppressor cells[J]. J Biol Chem, 2016, 291(41): 21771-21785. DOI: 10.1074/jbc.M116.726364.
[26]	de NARDO D, LABZIN LI, KONO H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3[J]. Nat Immunol, 2014, 15(2): 152-160. DOI: 10.1038/ni.2784.
[27]	ROSENBERGER CM, CLARK AE, TREUTING PM, et al. ATF3 regulates MCMV infection in mice by modulating IFN-gamma expression in natural killer cells[J]. Proc Natl Acad Sci U S A, 2008, 105(7): 2544-2549. DOI: 10.1073/pnas.0712182105.
[28]	HOETZENECKER W, ECHTENACHER B, GUENOVA E, et al. ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression[J]. Nat Med, 2011, 18(1): 128-134. DOI: 10.1038/nm.2557.
[29]	ZHU Q, WANG H, JIANG B, et al. Loss of ATF3 exacerbates liver damage through the activation of mTOR/p70S6K/ HIF-1α signaling pathway in liver inflammatory injury[J]. Cell Death Dis, 2018, 9(9): 910. DOI: 10.1038/s41419-018-0894-1.
[30]	KIM JY, PARK KJ, HWANG JY, et al. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis[J]. J Hepatol, 2017, 67(2): 349-359. DOI: 10.1016/j.jhep.2017.03.023.
[31]	FANG J, JI YX, ZHANG P, et al. Hepatic IRF2BP2 mitigates nonalcoholic fatty liver disease by directly repressing the transcription of ATF3[J]. Hepatology, 2020, 71(5): 1592-1608. DOI: 10.1002/hep.30950.
[32]	TU C, XIONG H, HU Y, et al. Cardiolipin synthase 1 ameliorates NASH through activating transcription factor 3 transcriptional inactivation[J]. Hepatology, 2020, 72(6): 1949-1967. DOI: 10.1002/hep.31202.
[33]	SHI Z, ZHANG K, CHEN T, et al. Transcriptional factor ATF3 promotes liver fibrosis via activating hepatic stellate cells[J]. Cell Death Dis, 2020, 11(12): 1066. DOI: 10.1038/s41419-020-03271-6.
[34]	LI XY, ZANG SB, ZHANG Y, et al. Low expression of activating transcription factor 3 in human hepatocellular carcinoma and its clinicopathological significance[J]. Pathol Res Pract, 2014, 210(8): 477-481. DOI: 10.1016/j.prp.2014.03.013.
[35]	WANG ZX, YIN SN, TIAN G, et al. Activating transcription factor 3 is downregulated in hepatocellular carcinoma and functions as a tumor suppressor by regulating cyclin D1[J]. Open Life Sci, 2016, 11(1): 367-371. DOI: 10.1515/biol-2016-0048.
[36]	LI X, ZANG S, CHENG H, et al. Over expression of activating transcription factor 3 exerts suppressive effects in HepG2 cells[J]. Mol Med Rep, 2019, 19(2): 869-876. DOI: 10.3892/mmr.2018.9707.
[37]	CHEN C, GE C, LIU Z, et al. ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression[J]. J Exp Clin Cancer Res, 2018, 37(1): 263. DOI: 10.1186/s13046-018-0919-8.
[38]	SHEN J, LIN H, LI G, et al. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth[J]. Oncotarget, 2016, 7(22): 32088-32099. DOI: 10.18632/oncotarget.8525.
[39]	WENG S, ZHOU L, DENG Q, et al. Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in hepatocellular carcinoma cells[J]. BMC Gastroenterol, 2016, 16: 25. DOI: 10.1186/s12876-016-0442-3.
[40]	LIN L, YAO Z, BHUVANESHWAR K, et al. Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2[J]. Carcinogenesis, 2014, 35(11): 2393-2403. DOI: 10.1093/carcin/bgu163.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (766) PDF downloads(61)

Research advances in the association between activating transcription factor 3 and chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2021.09.047

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in the association between activating transcription factor 3 and chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2021.09.047

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content